Lynda Charters

The long-term outcomes after primary scleral buckling procedures for rhegmatogenous retinal detachments showed high anatomic success, improved vision, and a good safety profile.

Danon disease is a rare, multisystem X-linked genetic disorder caused by variants in the LAMP2 gene. In children and young adults, it is defined overwhelmingly by its cardiac effects . What is far less appreciated is that the eye is frequently involved and that the retinal findings can appear before the systemic diagnosis is established.

A high-fat diet contributes to development of obesity, glucose intolerance, insulin resistance, and chronic inflammation. Evidence suggests that the negative effects may also reach the central nervous system A maternal high-fat diet can cause subtle retinal structural changes and sex-specific glial alterations, mainly in the peripheral retina of murine offspring.

Researchers in the UK have developed a new treatment approach for aniridia-related keratopathy (ARK), a rare genetic ocular disease, namely, a collagen scaffold that delivers limbal epithelial stem cells and stromal stem cells to the area affected by ARK. The treatment resulted in improved ocular surface scores and visual acuities.

The Class II recall alerts consumers and physicians to possible temporary or reversible health effects, but serious harm is unlikely.

Treating the cells with aflibercept or faricimab prevented a VEGF-A165–triggered increase of HUVEC cell-layer permeability (P = 0.0005). In the therapeutic/rescue setting, either drug temporally improved the cell-layer integrity (P = 0.0001).”

The status of the choriocapillaris may be a valuable factor when monitoring the macular microvasculature in prediabetes and early type 2 diabetes.

This article discusses the evolution of the body of information about Demodex blepharitis over the years, from the convening of a consensus panel to the realization that a new drug provides rapid relief to the ocular surface.

Fast ocular surface stabilization with dry eye lubricating drop: Piotr Wozniak, MD

Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.